Alzheon

Alzheon is a privately held clinical stage, biotechnology company based in Framingham, Massachusetts that was founded in 2013 by Martin Tolar. It focuses on developing medications by directly addressing the underlying pathology of neurodegenerative disorders.

Products

ALZ-801

The company's lead product candidate is ALZ-801, a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer's disease.

APOE4

The product is intended to focus on patients with mild Alzheimer's with the APOE4 genotype. It has been granted Fast Track Designation by the FDA in October 2017. Phase 3 clinical trials are planned for 2019.

ALZ-1903

Alzheon's product pipeline also has ALZ-1903, a pre-clinical candidate with the potential to inhibit amyloid misfolding.

Funding

Venture

On January 9, 2015 Alzheon completed a venture capital round with $3.1 million in funding from undisclosed investors.

Series A

On April 8, 2015 Alzheon completed their series A funding round with $10 million in funding from Ally Bridge Group (lead investor) and Scott H. Cohen.

Series B

On June 9, 2017 Alzheon is a completed their series B funding round with $15.8 million in funding from Ally Bridge Group.

Initial public offering

In April 2018, the company planned an $80 million IPO, but soon withdrew the offer. It re-announced later in August a $40 million IPO. However, that too was withdrawn in January 2019.